InnoCare Pharma マネジメント

マネジメント基準チェック /34

InnoCare Pharmaの CEO はJasmine Cuiで、 Aug2016年に任命され、の在任期間は 8.25年です。の年間総報酬はCN¥ 22.63Mで、 20.8%給与と79.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の5.73%を直接所有しており、その価値はHK$ 748.13M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と9年です。

主要情報

Jasmine Cui

最高経営責任者

CN¥22.6m

報酬総額

CEO給与比率	20.8%
CEO在任期間	8.3yrs
CEOの所有権	5.7%
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	9yrs

経営陣の近況

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30

CEO報酬分析

InnoCare Pharma の収益と比較して、Jasmine Cui の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-CN¥376m
Jun 30 2024	n/a	n/a	-CN¥471m
Mar 31 2024	n/a	n/a	-CN¥761m
Dec 31 2023	CN¥23m	CN¥5m	-CN¥631m
Sep 30 2023	n/a	n/a	-CN¥584m
Jun 30 2023	n/a	n/a	-CN¥867m
Mar 31 2023	n/a	n/a	-CN¥781m
Dec 31 2022	CN¥24m	CN¥4m	-CN¥887m
Sep 30 2022	n/a	n/a	-CN¥987m
Jun 30 2022	n/a	n/a	-CN¥296m
Mar 31 2022	n/a	n/a	-CN¥78m
Dec 31 2021	CN¥29m	CN¥3m	-CN¥65m
Sep 30 2021	n/a	n/a	CN¥60m
Jun 30 2021	n/a	n/a	-CN¥266m
Mar 31 2021	n/a	n/a	-CN¥329m
Dec 31 2020	CN¥120m	CN¥1m	-CN¥391m
Sep 30 2020	n/a	n/a	-CN¥2b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥17m	CN¥3m	-CN¥2b
Sep 30 2019	n/a	n/a	-CN¥742m
Jun 30 2019	n/a	n/a	-CN¥592m
Mar 31 2019	n/a	n/a	-CN¥571m
Dec 31 2018	CN¥26m	CN¥2m	-CN¥550m

報酬と市場: Jasmineの総報酬 ($USD 3.12M ) は、 Hong Kong市場 ($USD 481.65K ) の同規模の企業の平均を上回っています。

報酬と収益: Jasmineの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jasmine Cui (61 yo)

8.3yrs

在職期間

CN¥22,626,000

報酬

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jisong Cui	Co-Founder	8.3yrs	CN¥22.63m	5.73% HK$ 748.1m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	no data	CN¥4.06m	8.21% HK$ 1.1b
Xin Fu	Chief Financial Officer	less than a year	データなし	データなし
Nan Gao	Chief Operating Officer	3.3yrs	データなし	データなし
Yue Tan	Accounting Supervisor	no data	データなし	データなし
Xiangyang Chen	Chief Technology Officer	5.1yrs	データなし	0.0071% HK$ 926.1k
Junsu Wang	General Counsel	3.2yrs	データなし	データなし
Davy Ouyang	VP & Head of Biology	3.2yrs	データなし	データなし
Jeff Chen	Chief Commercial Officer	less than a year	データなし	データなし
Bei Yuan	Secretary of the Board	no data	データなし	データなし

3.2yrs

平均在職期間

52.5yo

平均年齢

経験豊富な経営陣: 9969の経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jisong Cui	Co-Founder	9yrs	CN¥22.63m	5.73% HK$ 748.1m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	9yrs	CN¥4.06m	8.21% HK$ 1.1b
Arnold Levine	Member of Scientific Advisory Board	no data	データなし	データなし
Yigong Shi	Non-Executive Director & President of Scientific Advisory Board	9yrs	データなし	0.18% HK$ 23.0m
Zemin Zhang	Member of Scientific Advisory Board	9yrs	データなし	データなし
Zhanguo Li	Member of Scientific Advisory Board	no data	データなし	データなし
Ronggang Xie	Non-Executive Director	3.7yrs	データなし	データなし
Lan Hu	Independent Non-Executive Director	4.7yrs	データなし	データなし
Dandan Dong	Independent Non-Executive Director	1.1yrs	データなし	データなし

9.0yrs

平均在職期間

55.5yo

平均年齢

経験豊富なボード: 9969の取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

InnoCare Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Innocare Pharma Limited Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Consensus estimates of losses per share improve by 19%

Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023)

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis

InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients

InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis

Consensus estimates of losses per share improve by 12%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

Consensus revenue estimates decrease by 16%

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates upgraded to CN¥0.38 loss

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.08 loss in 1Q 2022)

No longer forecast to breakeven

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Now 27% undervalued

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

Forecast to breakeven in 2024

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

マネジメント基準チェック /34